secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001641489-23-000068
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q3 net loss widens to $6.7M; cash drops to $8.2M
-----------------------------------------------------------------

- Net loss of $6.7M ($0.08 per share) vs $4.3M ($0.05) in Q3 2022.
- Cash and equivalents fell to $8.2M from $12.1M at Dec. 31, 2022.
- R&D expenses were $2.8M, down from $3.1M YoY on lower cadisegliatin costs.
- Appointed Dr. Thomas Strack as Chief Medical Officer on November 2, 2023.
- Received $4.4M from Reneo for repurchase of Reneo common stock on Nov 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000068/0001641489-23-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000068/vtvt-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001641489-23-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer